Timedora

How Diabetes Medicines Lower Blood Glucose

A guide to how major diabetes medicine classes lower blood glucose, how to match a therapeutic role to a class, and why their differences matter.

Match the medicine to its action

Start with the medicine’s main action

A useful way to identify diabetes medicine classes is to ask what the medicine changes: Does it replace insulin, affect the body’s response to insulin, influence insulin release, alter incretin signaling, or change how glucose is absorbed or excreted? These are different approaches, so the classes are not interchangeable.

The table summarizes each class by its main action and representative examples. Use the action—not just a name ending or an example—to match a class to a therapeutic role.

Match each class to its main action
ClassMain actionExamples
InsulinReplaces or supplements insulin; some forms cover meals, others provide background insulin.Lispro, aspart, regular insulin, NPH, glargine, degludec
BiguanidesReduce liver glucose production and improve the body’s response to insulin.Metformin
SulfonylureasStimulate pancreatic insulin release.Glipizide, glimepiride
MeglitinidesStimulate a shorter burst of insulin release around meals.Repaglinide, nateglinide
Thiazolidinediones (TZDs)Improve insulin sensitivity in body tissues.Pioglitazone
DPP-4 inhibitorsProlong incretin activity, helping regulate insulin release and glucose production.Sitagliptin, linagliptin
GLP-1 receptor agonistsMimic an incretin: increase glucose-dependent insulin release, reduce appetite, and slow stomach emptying.Semaglutide, dulaglutide, liraglutide
Dual GIP/GLP-1 receptor agonistsActivate two incretin pathways to improve glucose regulation.Tirzepatide
SGLT2 inhibitorsIncrease glucose excretion in urine.Empagliflozin, dapagliflozin
Alpha-glucosidase inhibitorsSlow carbohydrate digestion and absorption, reducing the post-meal glucose rise.Acarbose, miglitol
Amylin analoguesSupplement amylin effects, including slowing stomach emptying and reducing post-meal glucose rises.Pramlintide
Representative diabetes medicine classes grouped by their main glucose-lowering action.

Separate similar-sounding actions

Some classes affect insulin itself, but in different ways. Insulin therapy supplies insulin; it is essential in type 1 diabetes because the body does not make enough, and it may also be used in type 2 diabetes. Rapid- and short-acting forms cover meals, while intermediate- and long-acting forms provide background insulin. By contrast, sulfonylureas and meglitinides prompt the pancreas to release insulin. Meglitinides are described as producing a shorter burst around meals.

Other medicines make the body respond to insulin more effectively: biguanides reduce glucose production by the liver and improve insulin response, while TZDs improve sensitivity in body tissues. These are distinct from medicines that directly promote insulin release.

Incretin-related classes also have different actions. DPP-4 inhibitors prolong incretin activity; GLP-1 receptor agonists mimic an incretin hormone; and dual GIP/GLP-1 receptor agonists activate two incretin pathways. Do not treat these descriptions as interchangeable. GLP-1 receptor agonists also reduce appetite and slow stomach emptying, and their increase in insulin release is glucose-dependent.

Finally, distinguish changing glucose handling from changing insulin action: SGLT2 inhibitors increase glucose loss in urine, whereas alpha-glucosidase inhibitors slow carbohydrate digestion and absorption, reducing the rise after meals. Amylin analogues supplement amylin effects, including slowing stomach emptying and reducing post-meal glucose rises; they are used with insulin in selected cases.

Work through a class-matching question

If the stated role is to promote glucose leaving the body in urine, look for the action “increase glucose excretion in urine.” That identifies an SGLT2 inhibitor, such as empagliflozin or dapagliflozin—not metformin, which mainly reduces liver glucose production.

If the role is to replace insulin the body cannot produce, identify insulin therapy. This is essential in type 1 diabetes, though treatment choices also depend on diabetes type and the person’s health circumstances. Many people with type 2 diabetes use one or more non-insulin medicines.

Keep safety and treatment context in view

Sulfonylureas can cause . Insulin and medicines that stimulate insulin release can also cause low blood glucose; risks and benefits vary by medicine and patient. Some GLP-1 receptor agonist products have other approved uses, and some SGLT2 inhibitors have specific heart or kidney risk-reduction indications. These qualifications do not change the classes’ main actions, but they are reminders that matching an action to a class is not the same as choosing a treatment for an individual.

  • : A group of medicines with a shared main action.